Predicting changes in the pharmacokinetics of CYP3A‐metabolized drugs in hepatic impairment and insights into factors driving these changes
Physiologically based pharmacokinetic models, populated with drug‐metabolizing enzyme
and transporter (DMET) abundance, can be used to predict the impact of hepatic impairment …
and transporter (DMET) abundance, can be used to predict the impact of hepatic impairment …
Integrated Use of In Vitro and In Vivo Information for Comprehensive Prediction of Drug Interactions Due to Inhibition of Multiple CYP Isoenzymes
S Hozuki, H Yoshioka, S Asano, M Nakamura… - Clinical …, 2023 - Springer
Background Mechanistic static pharmacokinetic (MSPK) models are simple, have fewer data
requirements, and have broader applicability; however, they cannot use in vitro information …
requirements, and have broader applicability; however, they cannot use in vitro information …
[HTML][HTML] Performance verification of CYP2C19 enzyme abundance polymorphism settings within the simcyp simulator v21
C Sychterz, I Gardner, M Chiang, R Rachumallu… - Metabolites, 2022 - mdpi.com
Physiologically based pharmacokinetic (PBPK) modeling has a number of applications,
including assessing drug–drug interactions (DDIs) in polymorphic populations, and should …
including assessing drug–drug interactions (DDIs) in polymorphic populations, and should …
Human hepatocytes and cytochrome P450‐selective inhibitors predict variability in human drug exposure more accurately than human recombinant P450s
B Lindmark, A Lundahl, KP Kanebratt… - British journal of …, 2018 - Wiley Online Library
Background and Purpose Drugs metabolically eliminated by several enzymes are less
vulnerable to variable compound exposure in patients due to drug–drug interactions (DDI) …
vulnerable to variable compound exposure in patients due to drug–drug interactions (DDI) …
Prediction of human drug-drug interactions from time-dependent inactivation of CYP3A4 in primary hepatocytes using a population-based simulator
L Xu, Y Chen, Y Pan, GL Skiles, M Shou - Drug metabolism and disposition, 2009 - ASPET
Time-dependent inactivation (TDI) of human cytochromes P450 3A4 (CYP3A4) is a major
cause of clinical drug-drug interactions (DDIs). Human liver microsomes (HLM) are …
cause of clinical drug-drug interactions (DDIs). Human liver microsomes (HLM) are …
Physiologically based pharmacokinetic (PBPK) modeling for dynamical liver function tests and CYP phenotyping
J Grzegorzewski - 2023 - edoc.hu-berlin.de
Cytochrome P450 (CYP) phenotyping and dynamic liver function testing are essential
methods in clinical practice. These methods utilize the pharmacokinetics (PK) of test …
methods in clinical practice. These methods utilize the pharmacokinetics (PK) of test …
Physiologically based predictions of the impact of inhibition of intestinal and hepatic metabolism on human pharmacokinetics of CYP3A substrates
F Fenneteau, P Poulin, F Nekka - Journal of pharmaceutical sciences, 2010 - Elsevier
The first objective of the present study was to predict the pharmacokinetics of selected
CYP3A substrates administered at a single oral dose to human. The second objective was to …
CYP3A substrates administered at a single oral dose to human. The second objective was to …
Static and dynamic projections of drug-drug interactions caused by cytochrome P450 3A time-dependent inhibitors measured in human liver microsomes and …
E Tseng, H Eng, J Lin, MA Cerny, DA Tess… - Drug Metabolism and …, 2021 - ASPET
Cytochrome P450 3A (CYP3A) is a frequent target for time-dependent inhibition (TDI) that
can give rise to drug-drug interactions (DDI). Yet many drugs that exhibit in vitro TDI for …
can give rise to drug-drug interactions (DDI). Yet many drugs that exhibit in vitro TDI for …
Prediction of drug‐drug interactions using physiologically‐based pharmacokinetic models of CYP450 modulators included in Simcyp software
N Marsousi, JA Desmeules, S Rudaz… - … & drug disposition, 2018 - Wiley Online Library
In recent years, physiologically based PharmacoKinetic (PBPK) modeling has received
growing interest as a useful tool for the assessment of drug pharmacokinetics. It has been …
growing interest as a useful tool for the assessment of drug pharmacokinetics. It has been …
Prediction of CYP3A-mediated drug-drug interactions using human hepatocytes suspended in human plasma
J Mao, MA Mohutsky, JP Harrelson, SA Wrighton… - Drug metabolism and …, 2011 - ASPET
Cryopreserved human hepatocytes suspended in human plasma (HHSHP) represent an
integrated metabolic environment for predicting drug-drug interactions (DDIs). In this study …
integrated metabolic environment for predicting drug-drug interactions (DDIs). In this study …